Edgewise Therapeutics, Inc. (EWTX) /
The cash flow of Edgewise Therapeutics, Inc. over the past 6 years
Chart Edgewise Therapeutics, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2020–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Edgewise Therapeutics, Inc.'s operating cash flow was -$143.82M and its capital expenditures $256K, leaving free cash flow of -$144.07M. Free cash flow was below zero in all 6 years shown. It ranged from -$144.07M in fiscal 2025 to -$14.84M in fiscal 2020. Capital expenditures were highest in fiscal 2023, at $5.75M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$143.82M | $256K | -$144.07M |
| 2024ended Dec 31, 2024 | -$109.03M | $1.31M | -$110.34M |
| 2023ended Dec 31, 2023 | -$91.95M | $5.75M | -$97.69M |
| 2022ended Dec 31, 2022 | -$52.63M | $5.55M | -$58.18M |
| 2021ended Dec 31, 2021 | -$33.51M | $668K | -$34.17M |
| 2020ended Dec 31, 2020 | -$14.63M | $203K | -$14.84M |
Fiscal years as Edgewise Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Edgewise Therapeutics, Inc.
- The profitability of Edgewise Therapeutics, Inc.
- The debt of Edgewise Therapeutics, Inc.
- All of Edgewise Therapeutics, Inc.'s financials, charted
Companies of a similar size
- BBWIBATH & BODY WORKS, INC.
- KNTKKINETIK HOLDINGS INC.
- ARQTARCUTIS BIOTHERAPEUTICS, INC.
- FRSHFreshworks Inc.
- BYNDBEYOND MEAT, INC.
Not investment advice. This page shows what Edgewise Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.